glp-1 receptor agonists New Guidelines for Type 2 Diabetes in 2025 GLP-1 agonists approved for clinical
Description
Both contain tirzepatide at identical doses (2.5 mg to 15 mg)
Which peptide has better long-term safety data
The advancement of biosimilars and more economical production techniques may alleviate these issues
Addressing hypertriglyceridemia before starting GLP-1 receptor agonist therapy by implementing a low-carbohydrate diet and triglyceride-lowering medications could be preventive, even though GLP-1 receptor agonists will lower triglyceride levels
GLP-1 agonists have a fundamentally lower hypoglycemia risk
